These findings add to the accumulating evidence that the enhanced anti-tumor activity of combination anti-CTLA-4 and anti-PD-1 ICT is likely mediated by not only additive effects, but also through mechanisms distinct from the monotherapies19,23. This evidence concerns the gene CTLA4 and neoplasm.